Pancreatic Adenocarcinoma
Aggressive ductal adenocarcinoma with painless jaundice (head) or vague back pain (body/tail); poor prognosis.
Also known as: pancreatic cancer, pancreatic adenocarcinoma, PDAC
Overview
Malignant neoplasm of the pancreas; >85% are ductal adenocarcinomas (PDAC). Less common: cystic neoplasms (IPMN, MCN), neuroendocrine tumors, acinar cell carcinoma.
Epidemiology
~64,000 new cases and ~51,000 deaths annually in the US — 3rd leading cancer killer; projected to be 2nd by 2030. 5-year survival ~12% (recently improving). Most diagnosed at advanced stage. Median age at diagnosis 70.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Pancreatic Adenocarcinoma outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- Smoking (2-3× risk; most important modifiable)
- Chronic pancreatitis (especially hereditary — PRSS1 mutation)
- Diabetes mellitus — long-standing diabetes is risk factor; NEW-ONSET diabetes after age 50 can be paraneoplastic
- Obesity
- Family history (first-degree relative — 2-fold)
- Hereditary syndromes: BRCA1/2, PALB2, ATM, Lynch (MMR), Peutz-Jeghers (STK11), FAMMM (CDKN2A), familial pancreatitis (PRSS1)
- IPMN with high-risk features
- African American ethnicity
- Heavy alcohol use
- Helicobacter pylori (modest association)
Pathophysiology
Stepwise progression: normal duct → pancreatic intraepithelial neoplasia (PanIN-1 → -3) → invasive carcinoma. KRAS mutation (>90%), CDKN2A loss, TP53 mutation, SMAD4 loss. Dense desmoplastic stroma resists drug delivery and contributes to chemoresistance. Early perineural, lymphatic, and vascular invasion.
Clinical presentation
Symptoms
- Head tumors (~70%): painless obstructive jaundice (Courvoisier sign — palpable nontender gallbladder), pruritus, dark urine, pale stools, weight loss
- Body/tail tumors: vague epigastric or back pain, weight loss; late presentation
- New-onset diabetes after age 50 (consider as harbinger)
- Anorexia, weight loss, fatigue, weakness
- Steatorrhea (exocrine insufficiency)
- Depression (sometimes precedes diagnosis)
- Migratory superficial thrombophlebitis (Trousseau sign) — paraneoplastic
- Symptoms of metastatic disease: ascites, dyspnea, bone pain
Signs / physical exam
- Jaundice, scleral icterus
- Courvoisier sign — palpable nontender distended gallbladder
- Cachexia, temporal wasting
- Hepatomegaly (metastases)
- Virchow node (supraclavicular)
- Sister Mary Joseph nodule (periumbilical)
- Blumer shelf (rectal exam — pelvic peritoneal drop metastases)
- Ascites
- Migratory thrombophlebitis (Trousseau syndrome)
Classic findings
Painless jaundice + palpable nontender gallbladder + weight loss + new diabetes in patient >50 = pancreatic head cancer until proven otherwise.
Differential diagnosis
- Chronic pancreatitis — Calcifications, ductal changes; can mimic mass; weight loss less prominent; biopsy may be needed
- Autoimmune pancreatitis (IgG4) — Sausage-shaped pancreas, elevated IgG4, dramatic steroid response; can mimic cancer perfectly
- Cholangiocarcinoma — Painless jaundice; intra- or extrahepatic; MRCP, EUS-guided biopsy
- Distal CBD stone — Cholangitis features; absent mass on imaging
- Pancreatic neuroendocrine tumor — Hormone syndromes (gastrinoma, insulinoma, VIPoma); chromogranin A; better prognosis
- IPMN / mucinous cystic neoplasm — Cystic lesion; high-risk features (mural nodule, main duct >5 mm, jaundice, size >3 cm) warrant resection
- Pancreatic pseudocyst — History of pancreatitis; absence of mural nodule or septations on EUS
- Ampullary or duodenal carcinoma — Periampullary mass on EUS/ERCP
Diagnostic workup
Diagnostic criteria
Histologic confirmation by EUS-FNA preferred for non-resectable disease (allows molecular profiling). Resectable tumors may proceed to surgery based on imaging without pre-op biopsy if imaging is characteristic. AJCC TNM staging. Resectability classification: resectable, borderline resectable (vascular abutment), locally advanced (encasement of major vessels), metastatic.
Labs
- LFTs — direct hyperbilirubinemia, elevated alk phos in obstructive (head) tumors
- CBC, BMP, albumin (nutritional status)
- Lipase usually normal (unlike acute pancreatitis)
- CA 19-9 — elevated in ~80%; useful for monitoring response and recurrence; FALSE positive in cholestasis and Lewis-negative individuals (10% of population do NOT secrete CA 19-9)
- CEA — less specific
- Glucose, HbA1c (new diabetes association)
- Coagulation (vitamin K deficiency in cholestasis)
Imaging
- Multiphase pancreas-protocol CT (arterial and venous phases) — modality of choice for diagnosis, staging, and resectability assessment
- MRI/MRCP — better characterization of pancreatic cystic lesions and indeterminate liver lesions
- EUS — most sensitive for small lesions and lymph node assessment; tissue diagnosis via FNA
- ERCP — therapeutic (stenting for biliary decompression); double-duct sign (dilated CBD and pancreatic duct) — classic for head tumor
- PET-CT — selected cases for distant metastases
- Diagnostic laparoscopy with peritoneal washings — recommended for body/tail tumors and high-risk head tumors before resection (occult peritoneal disease in 15-25%)
Diagnostic algorithm
| Resectability Class | Imaging Criteria | Initial Management |
|---|---|---|
| Resectable | No arterial contact; ≤180° contact with SMV/PV without contour irregularity | Neoadjuvant chemo (increasingly) or upfront surgery + adjuvant chemo |
| Borderline resectable | Limited arterial contact (CHA, SMA <180°); SMV/PV reconstructable | Neoadjuvant chemo ± chemoradiation, then restage |
| Locally advanced (unresectable) | Encasement of SMA/celiac >180°; unreconstructable SMV/PV | Systemic chemo ± chemoradiation; palliative interventions |
| Metastatic | Distant metastases (liver, peritoneum, lung) | Palliative systemic therapy; best supportive care |
Treatment
First-line
- Multidisciplinary team management at high-volume center
- Stage- and resectability-directed therapy (see by_subtype)
- Pain control, nutritional support, biliary stenting for obstruction
- Pancreatic enzyme replacement for exocrine insufficiency
Resectable
- Neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine + nab-paclitaxel) increasingly favored over upfront surgery
- Pancreaticoduodenectomy (Whipple) for head tumors
- Distal pancreatectomy ± splenectomy for body/tail tumors
- Total pancreatectomy rarely indicated
- Adjuvant chemotherapy (modified FOLFIRINOX preferred — PRODIGE 24) for 6 months
Borderline resectable
- Neoadjuvant chemotherapy (FOLFIRINOX or gem-nab) ± chemoradiation
- Restage; surgery if downstaged to resectable
Locally advanced (unresectable)
- Systemic chemotherapy: FOLFIRINOX or gem-nab-paclitaxel
- Consider chemoradiation after induction chemotherapy in selected patients
- Palliative biliary and duodenal stenting for obstruction
- Celiac plexus neurolysis for pain
Metastatic
- First-line: FOLFIRINOX (good performance status) or gemcitabine + nab-paclitaxel
- BRCA1/2 or PALB2 mutation: platinum-based regimen and consider olaparib maintenance (POLO trial)
- MSI-H/dMMR (rare in PDAC): pembrolizumab
- NTRK or NRG1 fusion: targeted therapy in specialized centers
- Second-line: nanoliposomal irinotecan + 5-FU; gemcitabine-based if not previously used
- Best supportive and palliative care from diagnosis
Complications
- Biliary obstruction with jaundice and pruritus
- Gastric outlet obstruction (duodenal invasion)
- Pancreatic duct obstruction with exocrine insufficiency
- Cachexia and malnutrition
- Migratory thrombophlebitis (Trousseau)
- Venous thromboembolism (high risk)
- Pain — refractory, requires multimodal management including celiac plexus block
- Diabetes (type 3c) — brittle
- Depression
- Metastases — liver (most common), peritoneum, lung, bone
- Post-Whipple: pancreatic fistula, delayed gastric emptying, anastomotic leak, exocrine and endocrine insufficiency
PANCE pearls
- Painless obstructive jaundice + palpable nontender gallbladder (Courvoisier sign) in older adult = pancreatic head cancer until proven otherwise.
- Double-duct sign (dilated CBD and pancreatic duct) on cross-sectional imaging strongly suggests pancreatic head tumor.
- CA 19-9 is useful for surveillance and treatment response but NOT for diagnosis (false positives in cholestasis, false negatives in Lewis-negative individuals).
- New-onset diabetes after age 50, especially with weight loss, can be paraneoplastic — consider pancreatic imaging.
- Tissue diagnosis: EUS-FNA preferred for indeterminate or unresectable lesions; CT-guided biopsy if EUS unavailable; resectable lesions with characteristic imaging may proceed to surgery without preop biopsy.
- Whipple (pancreaticoduodenectomy) at high-volume centers reduces morbidity and mortality.
- FOLFIRINOX or gemcitabine + nab-paclitaxel are standard first-line systemic regimens.
- PRODIGE 24/CCTG PA.6: modified FOLFIRINOX adjuvant therapy significantly improves DFS and OS over gemcitabine in resected pancreatic cancer.
- BRCA1/2 mutations occur in 5-9% of PDAC — universal germline testing recommended; opens platinum and PARP inhibitor options.
- Universal germline genetic testing now recommended for ALL patients with PDAC (NCCN, ASCO).
- Hereditary pancreatic cancer surveillance: EUS or MRI annually starting age 50 (or 10 yr before youngest affected relative) in patients with BRCA1/2, Lynch, Peutz-Jeghers, FAMMM, hereditary pancreatitis.
References
- NCCN 2024 — NCCN Guidelines Version 2.2024 — Pancreatic Adenocarcinoma
- PRODIGE 24 — Conroy T et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. NEJM 2018;379:2395-2406
- POLO Trial — Golan T et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. NEJM 2019;381:317-327
- ACG 2018 — Aslanian HR et al. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals. Gastroenterology 2020;159:358-362
Practice Gastrointestinal questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.